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OBJECTIVES: The British government has decided to impose a system of value
based pricing (VBP) in England as part of a wide-ranging national health care sys-
tem (NHS) reform. The outcomes from this decision will have a number of conse-
quences for the NHS and the pharmaceutical industry alike. The objective of this
poster is to evaluate the impact of VBP implementation on the NHS and pharma-
ceutical industry specifically with regards to drug access, health care drug expen-
diture and promoting innovation.METHODS:A literature review was conducted in
order to understand health economists’ evaluations about VBP and stakeholders’
reaction to proposed reform. Ten stakeholders from academia, the pharmaceutical
industry and representative members of the NHS, were involved in qualitative
interviews to compare and contrast the views of health care workers, NICE and the
pharmaceutical industry about NHS reform and concept of value as it pertains to
VBP. RESULTS: VBP as expected has been quite a contentious and controversial
issue for the pharmaceutical industry with regards the proposed NHS reform.
NICE’s position on value based pricing based on cost-effectiveness analyses is ar-
guably not perfect, but it does define outcomes for the pharmaceutical industry in
a more transparent manner. Clinician stakeholders, including the proposed GP
commissioning groups will have difficulty in determining value without prescribed
criteria and specified guidelines based around innovation and value. It is also ques-
tionable whether VBP would indeed spur innovation of drug development or in fact
hamper research and development due to increased market access requirements
and decreased profitability in the pharmaceutical sector. CONCLUSIONS: The def-
initions of innovation and value in the pharmaceutical industry and the NHS have
different meanings for different stakeholders. A clearer understanding of VBP and
its expected outcomes would be helpful to bridge the gap between the pharmaceu-
tical industry and the NHS.
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OBJECTIVES: Syndrome of inappropriate antidiuretic hormone hypersecretion
(SIADH) is a common cause of hyponatremia contributing to 30-50% of hyponatre-
mia cases. Little is known of the influence of SIADH on health care resource utili-
zation. This study assessed the effect of SIADH on inpatient total and intensive care
unit (ICU) cost and length of stay (LOS), the likelihood of ICU admission, and 30-,
90-, and 180-day readmission. METHODS: The Premier hospital database was uti-
lized to identify US hospital inpatients discharged between January 1, 2007 and
June 30, 2009. Hyponatremic/SIADH patients were identified using primary or sec-
ondary ICD-9 codes (n430,731) and were matched to a control group (n430,731)
using exact matching on age, gender, provider region and 3M™ APR-DRG assign-
ment. Matching was further refined using propensity scores based on additional
patient and hospital covariates. Due to the contribution of congestive heart failure
and cirrhosis on hyponatremia development, these patients were excluded from
the analysis. The final analytic sample contained 65,973 SIADH patients and
407,874 non-hyponatremia/SIADH patients. Cost was analyzed using gamma re-
gression, LOS with negative binomial regression. ICU admission and hospital read-
mission were analyzed using multivariate logistic regression. RESULTS: In contrast
to non-SIADH patients, patients with SIADH had significantly higher total inpatient
cost (55.53%,CI52.53-58.60;p.0001), ICU cost (38.07%;CI33.18-43.15;p0.0001),
total LOS (45.11%,CI43.20-47.03;p0.0001), and ICU LOS (42.72%,CI38.36-47.23;
p.0001). SIADH patients were significantly more likely to be admitted to the ICU
(OR2.131;p.0001), and readmitted at 30- (OR1.399;p0.0001), 90- (OR1.495;
p0.0001), and 180-days (OR1.459;p0.0001) in comparison with non-SIADH
patients. CONCLUSIONS: The presence of SIADH in hospitalized patients is signif-
icantly associated with increased total and ICU cost and LOS, likelihood of ICU
admission, and likelihood of readmission.
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OBJECTIVES: To describe how Thailand use evidence on country’s burden of dis-
ease and cost-effectiveness of health interventions from the 2nd edition Disease
Control Priority in Developing Countries (DCP2) to set priorities in health sector
investment in the National Health Development Plan. METHODS: The study ap-
plies comprehensive literature reviews, secondary data analyses, interview of key
informants and meeting among stakeholders to answer four specific OBJECTIVES:
a) burden of disease (BOD) priorities; b) health interventions currently imple-
mented in Thailand against what recommended by DCP2; c) costs of top-ten BOD in
terms of medical expenditure, productivity loss due to life loss and morbidity; and
d) assessment of medium term economic framework in different scenario.
RESULTS: Since 1999 there has been an increasing trend in BOD attributable from
alcohol and tobacco consumption, consumption of high fat high calorie diet, lack of
fibre food and physical activities, increasing incidence of diabetes mellitus, hyper-
tension and high blood lipid, traffic injuries, overweight and obesity. Evidence from
the share of DALY loss, productivity loss and absenteeism from morbidity indicates
three national health priorities: HIV/AIDS; traffic injuries and diabetes mellitus.
Total health expenditure in 2009 was 179 USD per capita, 4.3% of GDP, and mostly
spent on curative services, only 4.5% of that was for disease prevention and health
promotion. CONCLUSIONS: Thailand can invest more on health of the population,
in particular on disease prevention and health promotion to address three national
health priorities: HIV/AIDS, traffic injuries and diabetes mellitus through cost effective
interventions in and outside the health sector. The most probable scenario for increas-
ing investment in health promotion and disease prevention is to double the amount of
investment for health promotion and disease prevention. Also, resources can be mo-
bilized from local administrations and communities, and should be managed by effi-
cient and accountable agency with effective mechanisms.
PHP73
GOVERNMENT REDUCES PUBLIC PHARMACEUTICAL EXPENDITURE IN
HUNGARY: RATIONAL DECISIONS IN CHALLENGING ECONOMIC TIMES?
Inotai A1, Merész G1, Kalo Z2
1Syreon Research Institute, Budapest, Hungary, 2Eötvös Loránd University, Budapest, Hungary
OBJECTIVES: Scarcity of public resources, especially in challenging economic
times, draws attention to the expenditure on pharmaceuticals. Over the next 3
years the Hungarian government plans to reduce the public pharmaceutical spend-
ing by 35%. Our objective was to assess the current level of pharmaceutical expen-
diture in Hungary by taking into account the economic status of the country and
benchmarks from other OECD countries with special focus on Visegrad countries
(Czech Republic, Slovakia, Poland, Hungary). METHODS: We completed interna-
tional cross sectional and cluster analysis based on OECD Health Data 2010 and
longitudinal analysis of public pharmaceutical expenditure in Hungary. RESULTS:
The cluster analysis indicates that pharmaceutical spending is relatively higher in
middle-income countries compared to high income countries above 30’000 USD
GDP/capita (1.89 vs. 1.41% of GDP%, p0.04; 23.58% vs. 14.14% of total health ex-
penditure, p0.001), as prices of pharmaceuticals are not adjusted to local price
levels as opposed to prices of other health care services. International trends of the
global pharmaceutical market are also valid in Hungary. The public pharmaceuti-
cal spending is close to the average of Visegrad countries, but the private pharma-
ceutical spending is the highest. The annual real growth rate of public pharmaceu-
tical spending was only 1.0% between 1994-2010, whilst increased private funding
(mainly out of pocket payments) was the major growth driver of total pharmaceu-
tical expenditure in Hungary.CONCLUSIONS:Cost-containment of public pharma-
ceutical spending was very successful in the last 15 years. The burden of pharma-
ceutical market growth has been shifted to private households. The proposed
public budget cut translates to over 30% decrease in real public pharmaceutical
spending from 1994 to 2014. As morbidity and mortality indicators of the Hungar-
ian population are extremely unfavourable, current evidences and international
benchmarks do not justify significant reduction of the public pharmaceutical bud-
get.
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Greek law (3816/2010) sets a list for serious diseases products (89 in total) which can
be dispensed either through public hospitals or retail pharmacies for non hospital-
ized patients. Each distribution channel incurs different costs for the NHS (public
hospitals/SSFs). OBJECTIVES: Estimate potential savings for GR NHS (Social Secu-
rity Funds & Hospitals) through dispensing products of serious diseases through
hospital pharmacies instead of retail pharmacies. METHODS: Data derived from
drug reimbursement database of OGA (Agriculture SSF) covering 20% of the GR
population. The data represent actual reimbursement amounts to private pharma-
cies, from January to April 2011, extrapolated for the whole 2011. The price calcu-
lations were based on the following formulas: 1) Public hospitals buy at hospital
price (HP)VAT from pharmaceutical companies; 2) Public hospitals charge whole-
saler price3% premium to SSFs; and 3) Retail pharmacies charge SSFs retail price
(calculated as hospital price 2,5%wholesaler margin 18% pharmacy margin
VAT). RESULTS: Based on the mean of 5950 prescriptions per month the average
value paid by OGA to the retail pharmacies was €1042 per prescription. By changing
dispensing channel, via hospital, the mean cost per prescription for OGA was esti-
mated at €930.93. Since both SSFs & hospitals are part of NHS, the actual cost of
NHS/prescription is the hospital cost estimated at €818.72 and the estimated hos-
pital gain per prescription is €112.21. The actual gain for NHS per prescription is
€223.28. The extrapolated gain for OGA for 2011 is estimated at €7,930.398 while for
NHS is €15,942.192. CONCLUSIONS: Distribution of products for serious diseases
via hospital pharmacies, leads to considerable savings for NHS and SSFs while
ensuring considerable gains for hospitals, under specific conditions (hospital per-
sonnel, budget, immediate payment by SSF). The expansion of the list is of absolute
priority for reducing the NHS spending. More savings can be achieved by dispens-
ing L3816 products through the newly formed unified health care fund (EOPYY)
covering 90% of total population.
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OBJECTIVES: To estimate the daily cost of intensive care unit (ICU) stay in France
using a microcosting methodology. METHODS: A multicentre prospective cost
analysis study was carried out among 23 French ICUs randomly selected from the
French National Hospital database stratified by hospital category (regional, univer-
sity and private non profit). Each ICU enrolled 5 adult patients admitted from May
to October, 2009, selected at random, with a simplified acute physiology score
(SAPSII)15 at admission and with at least 1 reanimation medical act. All health-
care resources used by each patient over a 24-hour period were recorded, as well as
the time spent by all hospital staff involved in the patient’s management. All re-
sources identified were valued from a hospital perspective (reference year 2009)
based on unit cost data provided by each centres. Bi-variant analyses were carried
out to identify potential cost-drivers. RESULTS: A total of 104 patients were en-
rolled by 21 ICUs (14 polyvalent, 3 surgical and 4 medical) were included. The mean
age of patients was 62.3 years (SD 14.9); 64% were male; 86% were mechanically
ventilated and the median Sequential Organ Failure Assessment (SOFA) score was
6 (SD 4.3). The average daily cost of ICU per patient was €1,424 (SD €520). Staff time
represented the largest component of this cost (43%) followed by overheads, capi-
tal, hotel and nutrition assigned to the ICU (22.9%). Medication and consumables
used accounted for 18.6% of the total cost. The majority of the cost (59%) was
patient-dependant. The two main patient-dependant factors associated with sig-
nificantly higher costs were: a high SOFA score and being on continuous mechan-
ical ventilation. CONCLUSIONS: This first French microcosting study in ICU dem-
onstrates that the cost per day of ICU care is substantially depends on the patient’s
medical profile and mainly driven by labour components.
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OBJECTIVES: Budget impact analysis (BIA) is a tool used to predict and understand
the potential financial impact of introducing a new health care intervention into a
health care system that has finite financial resources. Czech laws only prescribe
duty to attach BIAs to the applications for new drug reimbursements without spec-
ifying guidelines how to prepare BIA. We analyzed the differences between the BIA
in the applications and the real expenditures of the public health insurance.
METHODS: We have selected 3 applications of new drugs (romiplostin, lenalido-
mid, bevacizumab) submitted in year 2009 (or an established drug in new indica-
tion) and compared submitted BIA estimates for year 2010 with the real expendi-
tures in the same year. We also compared the methods in the submitted BIAs with
the Impact Analysis Guidelines published by Patented Medicine Prices Review
Board (Canadian National Drug Reimbursement Authority) to identify potential
reasons of differences. RESULTS: We found differences in the predicted number of
patients, average cost of drug application and total impact on the public health
insurance. CONCLUSIONS: The comparison with standard guidelines identified
the key areas to be addressed in the future Czech legislative to improve the quality
of submitted BIAs. The inaccuracies were mainly caused due to a) Lack of data
sources and their transparency; b) Inaccurate or misapplied assumptions; c) Inap-
propriate choice of comparators; and d) Overall quality, e.g. false interpretation of
referenced studies conclusions.
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OBJECTIVES: To assess the relative ability of several health-related quality of life
(HRQOL) measures to predict future health care expenditures. METHODS: Data
from the Medical Expenditure Panel Survey (MEPS) for years 2003 (Panel 4, Round 2)
and 2004 were used for study purposes and weighted in order to gain a population-
level analysis. Applying the Model of Health Services Use, predisposing (age, gen-
der, race, years of education, and marital status) and enabling (insurance type,
employment status, family size, and annual household income) variables were
combined with varying need variables (SF-12 PCS, SF-12 MCS, EQ-5D Index, EQ-5D
VAS, single-item core questions of perceived physical and mental health status, or
a combination thereof) and used to predict overall healthcare expenditures, one
year after survey, in multivariate linear regression models. The individual R2 val-
ues were used for model comparison. RESULTS: The final dataset was composed of
9304 respondents, representing over 186 million US residents. The base model of
only predisposing and enabling covariates resulted in an R2 value of 0.067. The
model using both the SF-12 PCS and MCS values as need variables resulted in the
highest R2 value of all models run: 0.094. Use of the SF-12 MCS or the single-item
perceived mental health core item as need variables only marginally out-per-
formed the base model, both resulting in R2 values of 0.069. The EQ-5D VAS and
Index as well as the physical health perception core measure values were similar,
ranging from 0.0821 to 0.0868. CONCLUSIONS: The combined use of the SF-12 MCS
and PCS measures as need variables in the Model of Health Services Use performed
better than the other HRQOL measures in the MEPS dataset in predicting future
health care expenditures.
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OBJECTIVES: On January 1, 2011, the rapid benefit assessment (RPA) as basis for
central price regulations was introduced for new drugs in Germany. It requires the
pharmaceutical manufacturer to submit a value dossier. The objective was to in-
vestigate converging trends in budget impact analysis (BIA) requirements in se-
lected countries and to compare them to the German RPA. METHODS: We con-
ducted a systematic review of national guidelines on BIA requirements for the
pricing and reimbursement process of pharmaceuticals in 14 countries across the
western world (Europe, North America, Israel). Where needed informal stakeholder
interviews were used to supplement lacking information. The information was
extracted and evaluated based on 10 characteristics obtained from the “ISPOR
Principles of Good Research Practice for Budget Impact Analysis” (Mauskopf et al.
2007). RESULTS:All of the investigated countries except for Germany, Scotland and
Norway consider the direct medical budget impact of new pharmaceuticals in their
reimbursement decision making. In Germany, only the maximum annual direct
intervention costs have to be stated. Although Norway and Scotland request no BIA
from a payer’s perspective the drug’s impact on the change in medical resource
consumption is analyzed as part of the pharmacoeconomic and comparative ef-
fectiveness analyses. 8 countries demand a self-contained BIA complementary to
the broader health economic evaluation, while 3 countries deal with financial con-
sequences as part of the economic evaluation. In all countries except for Germany
economic consequences for the healthcare budget have to be presented for at least
2-5 years on an annual basis to capture medium to long term savings and expen-
ditures associated with changes in the medical resource utilization following a
drug’s availability in the market. CONCLUSIONS: All investigated countries except
Germany consider changes in the resource consumption and their financial con-
sequences (even for a medium term period) for decision making.
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OBJECTIVES: The efficient use of resources requires explicit criteria for setting
health care research priorities. We assessed whether economic evaluations of
healthcare interventions are directed to priority diseases in the allocation of pub-
lic-funded research in the Spanish National Health System. METHODS: We ana-
lyzed data from a systematic review of economic evaluations performed in Spain
(period 1983-2008). Reports were grouped according to the source of funding. We
included a representative sample of public funds allocated to research projects
(2006/2007 calls of the Instituto de Salud Carlos III, Spanish Ministry of Science and
Innovation). Both economic evaluations and research projects were classified ac-
cording to the main disease causes, following the classification proposed by the
World Health Organization in its Global Burden of Disease study. We calculated
Spearman correlation coefficients (r) between the public funds and economic
evaluations. RESULTS: A total of 1410 research projects (equivalent to €125.6 mil-
lion) and 477 economic evaluations were identified and could be categorized in 20
groups and 40 specific causes of diseases. For major groups (n20), the associations
were: total economic evaluations (r0.80, p 0.001), economic evaluations funded
by for-profit organizations (r0.77, p 0.001) and those funded by nonprofit orga-
nizations (r0.85, p 0.001). For specific disease-causes (n40): total economic
evaluations (r0.52, p0.001), economic evaluations funded by for-profit organiza-
tions (r0.38, p0.016) and funded by nonprofit agencies (r0.61, p0.001).
CONCLUSIONS: The distribution of priorities is similar between economic evalua-
tions and public research funds allocated to specific diseases. However, the optimal
level of these distributions could be determined with additional analyses on the
impact of research results in reducing the burden of disease in the population.
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OBJECTIVES: The aim of this study is to describe the experience with the Belgian
policy that obliges physicians to prescribe minimum quota of cheap medicines and
to document the outcomes of this policy using publicly available data. METHODS:
Data were obtained from yearly feedback reports of the policy on the website of the
Belgian third-party payer (RIZIV/INAMI) which were sent to all physicians. Data
were derived from Farmanet, a database where all data of prescriptions of reim-
bursed medicines from all physicians in Belgium are collected. RESULTS: All
groups of general practitioners, specialists and dentists reached their minimum
percentages every year from 2006 until 2009. The percentage of cheap medicines (in
DDD) increased from 22.9% in January 2005 to 44.2% of all prescribed medicines in
ambulatory care in December 2009. The percentage of generic medicines increased
from 12.10% in 2004 to 24.03% of all prescribed medicines in ambulatory care in
2008. When a physician prescribed a cheap medicine, this was an original medicine
whose price had dropped to the reference price level in 41.5% of cases in August
2009. CONCLUSIONS: The policy of prescribing quota for cheap medicines was not
only associated with increased prescribing of generic medicines during 2004-2008,
but also increased prescribing of original medicines whose price had dropped to
the reference price level. The potential for prescribing generic medicines has not
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